LINKÖPING, Sweden [24 February, 2017] – In 2016, UK Biobank launched the world’s largest health imaging study, with the aim to shed new light on and to improve the prevention, diagnosis and treatment of a wide range of diseases.
For ten years, UK Biobank has gathered genetic, blood, lifestyle, and health record data on its 500,000 participants. The second phase, the health imaging study, focuses on dedicated imaging of the brain, heart, bones, carotid arteries, and body composition of 100,000 UK Biobank participants.
It is well-understood that fat distribution, rather than the total amount of fat, is vital in determining individual risk of disease development. As such, AMRA was selected to perform the precise fat and muscle measurement of all 100,000 UK Biobank abdominal MRIs. AMRA then developed an international collaboration with Pfizer Inc., Imperial College and Westminster University to assess the first 6,000 UK Biobank subjects for insights into metabolic disease risk factors. AMRA’s ultimate aim as a company and within UK Biobank is to redefine obesity, understand individual metabolic risk, and to predict & prevent metabolic disease.
AMRA is proud to announce that the first 1,000 datasets analysed for body composition are now available for public access in UK Biobank. As UK Biobank is an open resource for health-related research, global scientists within academia and industry may apply for access to UK Biobank data to support their own research.
For information on AMRA’s data within UK Biobank, please visit: http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=149
For information on how to apply for UK Biobank access, please visit: http://www.ukbiobank.ac.uk